209256-42-8

Basic information

• Product Name: 2,3-DIHYDRO-4-BENZOFURANCARBOXALDEHYDE
• Synonyms: 2,3-DIHYDRO-BENZOFURAN-4-CARBALDEHYDE;2,3-DIHYDRO-4-BENZOFURANCARBOXALDEHYDE;4-Benzofurancarboxaldehyde, 2,3-dihydro- (9CI);4-Benzofurancarboxaldehyde, 2,3-dihydro-;Tasimelteon INT
• CAS NO: 209256-42-8
• Molecular Formula: C₉H₈O₂
• Molecular Weight: 148.16
• Product Categories: ALDEHYDE
• Mol File: 209256-42-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 276℃
• Flash Point: 132℃
• Appearance: /
• Density: 1.222
• Vapor Pressure: 0.005mmHg at 25°C
• Refractive Index: 1.612
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2,3-DIHYDRO-4-BENZOFURANCARBOXALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIHYDRO-4-BENZOFURANCARBOXALDEHYDE(209256-42-8)
• EPA Substance Registry System: 2,3-DIHYDRO-4-BENZOFURANCARBOXALDEHYDE(209256-42-8)

Safety Data

• Hazardous Substances Data: 209256-42-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Dihydro-4-benzofurancarboxaldehyde is used as a key intermediate in the synthesis of macroline derivatives, which are inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B. This application is significant for the development of new treatments against tuberculosis, a disease that poses a significant global health challenge.

InChI:InChI=1/C9H8O2/c10-6-7-2-1-3-9-8(7)4-5-11-9/h1-3,6H,4-5H2

Upstream product

• 166599-84-4 benzofuran-4-carboxylic acid 
• 209256-40-6 2,3-dihydrobenzofuran-4-carboxylic acid 
• 68-12-2 N,N-dimethyl-formamide 
• 289058-20-4 4-chloro-2,3-dihydro-1-benzofuran 
• 30595-79-0 2-(2,6-dichlorophenyl)ethan-1-ol 
• 79-37-8 oxalyl dichloride 
• 209256-41-7 (2,3-dihydro-benzofuran-4-yl)-methanol 
• 230642-84-9 4-ethenyl-2,3-dihydro-1-benzofuran 
• 186191-19-5 m-(2-bromoethyloxy)benzaldehyde 
• 864147-85-3 benzyl-(3-vinyloxy-benzylidene)-amine 
• 83228-39-1 3-vinyloxy-benzaldehyde 

Downstream Products

• 209256-81-5 (trans)-N-methoxy-N-methyl-3-(2,3-dihydrobenzofuran-4-yl)propenamide 
• 335064-60-3 C₁₂H₁₂O₂ 
• 209257-15-8 1-[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methanamine 
• 609799-22-6 [14C]-Tasimelteon 
• 209257-15-8 trans-[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methanamine 

Relevant articles and documents

Synthesis method of 2,3-dihydro-1-benzofuran-4-carbaldehyde

The invention relates to a synthesis method of 2,3-dihydro-1-benzofuran-4-carbaldehyde. The formula of 2,3-dihydro-1-benzofuran-4-carbaldehyde can be shown in the formula (I). The synthesis method comprises the steps of making a compound shown in the formula (II) be subjected to intramolecular cyclization reaction so as to produce a compound shown in the formula (III) under the existence of alkali metal compounds and Cu(1); making the compound shown in the formula (III) be subjected to reaction together with magnesium and a compound shown in the formula R3CONR1R2(IV) so as to obtain the compound shown in the formula (I). According to the synthesis method of 2,3-dihydro-1-benzofuran-4-carbaldehyde, reaction conditions are mild, procedures are simple, byproducts are few, and thus the synthesis method of 2,3-dihydro-1-benzofuran-4-carbaldehyde is suitable for being applied to large scale industrial production.

CYCLOPROPYL DIHYDROBENZOFURAN MODULATORS OF MELATONIN RECEPTORS

The present invention relates to new cyclopropyl dihydrobenzofuran modulators of melatonin receptors, pharmaceutical compositions thereof, and methods of use thereof.

Heterocyclic sodium/proton exchange inhibitors and method

Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R1, R2, R3 and R4 are as defined herein, and where X is N. R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.

ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD

Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C-R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.

Annulation of aromatic imines via directed C-H bond activation

A directed C-H bond activation approach to the synthesis of indans, tetralins, dihydrofurans, dihydroindoles, and other polycyclic aromatic compounds is presented. Cyclization of aromatic ketimines and aldimines containing alkenyl groups tethered at the meta position relative to the imine directing group has been achieved using (PPh3)3RhCl (Wilkinson's catalyst). The cyclization of a range of aromatic ketimines and aldimines provides bi- and tricyclic ring systems with good regioselectivity. Different ring sizes and substitution patterns can be accessed through the coupling of monosubstituted, 1,1- or 1,2-disubstituted, and trisubstituted alkenes bearing both electron-rich and electron-deficient functionality.

BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS

Novel derivatives of benzodioxa alkylene ethers are provided which are useful as melatonergic agents.

Acyl guanidine sodium/proton exchange inhibitors and method

Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure STR1 wherein n is 1 to 5; X is N or C--R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.